What is the CVR number of Vetrepharm ApS?

Vetrepharm ApS is registered with CVR / Virk under CVR 15206802.

What is the revenue of Vetrepharm ApS?

Vetrepharm ApS reported revenue of DKK -40K in 2019.

Vetrepharm ApS employs 1 people as of the latest annual report.

Vetrepharm ApS's registered address is Præstelunden 3.

APSDissolvedAdvertising protection

CVR 15206802Præstelunden 3, 7330 BrandeWholesale of pharmaceutical and medical goods· NACE 4646Est. 1991 · 35 years old1 employees

Actively employed in the business

Name	Role	Member since
Former (5)
SS SR, STATSAUTORISERET REVISIONSAKTIESELSKAB Audit	Audit	1991 – 1994
ET Erik Tronborg Andersen Audit	Audit	1991 – 1992
KJ Kristian Johannes Borum Management	Management	1991 – 2020
IK Ingerlise Kofod Management	Management	1991 – 2009
PE Per Emil Hasselbalch Stakemann Management	Management	1991 – 1992

Non-executive oversight

Name	Role	Member since
Former (13)
US Ulf Svejgaard Poulsen Board of Directors	Board of Directors	1991 – 1992
NB Ninna Bork Christensen Board of Directors	Board of Directors	2009 – 2018
NB Nina Boelsgaard Kieffer Board of Directors	Board of Directors	2003 – 2009
MK Michael Keith Thompson Board of Directors	Board of Directors	1991 – 1999
KL Kurt Langbo Board of Directors	Board of Directors	1991 – 2003
PM Poul Michael Bjørnskov Board of Directors	Board of Directors	2003 – 2009
FA Fiona Anne Fox Board of Directors	Board of Directors	1991 – 1996
UB Ulf Bjerre Chairman	Chairman	2003 – 2009
HA Hugh Alasdair Fell Board of Directors	Board of Directors	2002 – 2002
KB Klaus Bork Hansen Chairman	Chairman	2009 – 2018
ER Eli Rubech Rasmussen Board of Directors	Board of Directors	1991 – 2003
SS Susanne Saul Stakemann Chairman	Chairman	1991 – 1992
MK Mariane Kirstine Kempel Board of Directors	Board of Directors	1999 – 2000

As of last annual report

Shareholder	Type	Ownership	Votes	Since
KB HOLDING, BRANDE ApS	Company	100%	100%	2009

Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.